Yi Zhou
Vertex Pharmaceuticals
19 Papers
456 Citations
Yi Zhou is an academic researcher from Vertex Pharmaceuticals. The author has contributed to research in topics: Hepatitis C virus & Telaprevir. The author has an hindex of 10, co-authored 19 publications.
Chat about Author
Papers
Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment-Naive Subjects
Doug J. Bartels,Yi Zhou,Eileen Z. Zhang,Michelle Marcial,Randal Byrn,Thomas Pfeiffer,Ann M. Tigges,Bambang S. Adiwijaya,Chao Lin,Ann D. Kwong,Tara L. Kieffer +10 more
TL;DR: High levels of naturally occurring protease inhibitor-resistant variants were uncommon in HCV treatment-naive patients, and as new HCV agents are evaluated in clinical trials, it will be important to monitor the effect of baseline variants on sensitivity.
226
Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease
Yi Zhou,Doug J. Bartels,Brian L. Hanzelka,Ute Müh,Yunyi Wei,Hui-May Chu,Ann M. Tigges,Debra L. Brennan,B. Govinda Rao,Lora Swenson,Ann D. Kwong,Chao Lin +11 more
TL;DR: In this article, the authors used purified protease domain proteins and reconstituted HCV subgenomic replicons for phenotypic characterization of substitutions in the NS3 protease domains.
102
Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.
Yi Zhou,Ute Müh,Brian L. Hanzelka,Doug J. Bartels,Yunyi Wei,B.G. Rao,Debra L. Brennan,Ann M. Tigges,Lora Swenson,Ann D. Kwong,Chao Lin +10 more
TL;DR: It was demonstrated that replicon cells containing substitutions at NS3 protease residue 155 remain fully sensitive to interferon α or ribavirin, and these variant replicons were shown to have reduced replication capacity compared with the wild-type HCV replicon in cells.
93
Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples
Eileen Z. Zhang,Doug J. Bartels,J. Dan Frantz,Sheila Seepersaud,Judith A. Lippke,Benjamin Shames,Yi Zhou,Chao Lin,Ann D. Kwong,Tara L. Kieffer +9 more
TL;DR: This assay allows viral sequencing of all regions targeted by the most common DAAs currently in development, as well as the possibility to determine linkage between variants conferring resistance to multiple DAAs used in combination therapy.
In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir.
Min Jiang,Nagraj Mani,Chao Lin,Andrzej Ardzinski,Michelle Nelson,Dugan Reagan,Doug J. Bartels,Yi Zhou,Olivier Nicolas,B. Govinda Rao,Ute Müh,Brian L. Hanzelka,Ann M. Tigges,Rene Rijnbrand,Tara L. Kieffer +14 more
TL;DR: All telaprevir-resistant variants remained fully sensitive to alpha interferon, ribavirin, and HCV NS5B nucleoside and nonnucleoside polymerase inhibitors and their replication capacity was lower than that of the wild-type replicon.
29